Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
96.5M
-
Number of holders
-
153
-
Total 13F shares, excl. options
-
78.7M
-
Shares change
-
+5.24M
-
Total reported value, excl. options
-
$827M
-
Value change
-
+$46.3M
-
Put/Call ratio
-
0.48
-
Number of buys
-
85
-
Number of sells
-
-81
-
Price
-
$10.51
Significant Holders of AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) as of Q4 2024
219 filings reported holding AVDL - AVADEL PHARMACEUTICALS PLC - Common Stock as of Q4 2024.
AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) has 153 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.7M shares
of 96.5M outstanding shares and own 81.53% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (14.1M shares), GENDELL JEFFREY L (6.33M shares), BlackRock, Inc. (5.44M shares), Polar Capital Holdings Plc (4.41M shares), Two Seas Capital LP (4.3M shares), BRAIDWELL LP (4.11M shares), VANGUARD GROUP INC (3.95M shares), Vivo Capital, LLC (2.68M shares), CITADEL ADVISORS LLC (2.59M shares), and WEALTH EFFECTS LLC (2.34M shares).
This table shows the top 153 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.